jRCT2011210059进行中（未招募）不适用
A MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-BLIND PHASE III CLINICAL TRIAL OF OBINUTUZUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 24
- 主要终点
- complete renal response
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 75age old under（—）
- 性别
- All
入选标准
- •(1)Patients living in Japan aged 18-75 years
- •(2)Active Class III or IV or III/IV+V LN (not including Class III(C),IV(C))diagnosed according to ISN/RPS 2003 Classification Criteria by renal biopsy performed in the 6 months prior to ICF or during screening
- •(3)SLE according to the EULAR/ACR 2019 Classification Criteria, which are met by the presence of Class III or IV LN refer to (2) and positive antinuclear antibody status at the time of screening or in previous examinations
- •(4)UPCR >= 1 on a 24-hour collection
- •(5)Patient who receipt of at least one dose of steroid pulse therapy (methylprednisolone >= 250 mg or equivalent) for treatment to active LN within 6 months prior to screening or during screening (until prior to Day 1 obinutuzumab or placebo)
- •(6)For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use appropriate contraception, and agreement to refrain from ovum donation (18 months after the final dose of obinutuzumab or placebo and 6 weeks after the final dose of MMF)
- •(7)For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating sperm(90 days after the final dose of MMF)
排除标准
- •(1)eGFR<30 mL/min/1.73 m2(eGFR creat equation)or Severe renal impairment patient who need for dialysis or renal transplantation
- •(2)Sclerosis in > 50% of glomeruli
- •(3)Presence of rapidly progressive glomerulonephritis, defined by any of the following:
- •Crescent formation in >= 50% of glomeruli assessed
- •Sustained doubling of the serum creatinine reference range within 2 months prior to screening
- •(4)Rapidly progressive glomerulonephritis as determined by the investigator
- •(5)Central nervous system lupus
- •(6)Any biologic agents that deplete B cells or plasma cells (Anti-CD 19 antibody, anti-CD 20 antibody, etc) within 9 months prior to screening or during screening.
- •(7)Calcineurin inhibitors within 4 weeks prior to screening or during screening
- •(8)Cyclophosphamides within 2 months prior to screening or during screening
- •(9)Any biologic therapy (drugs other than B cell or plasma cell depleting drugs that may affect the safety of subjects or evaluation of this study) within 2 months prior to screening or during screening
- •(10)Oral inhibitors of Janus-associated kinase (JAK), Bruton's tyrosine kinase (BTK), or tyrosine kinase 2 (TYK2) or any investigational agent within 2 months prior to screening or during screening
- •(11)Any live vaccine within 27 days prior to screening or during screening
结局指标
主要结局
complete renal response
时间窗: Week 76
To compare the efficacy of obinutuzumab when combined with standard-of-care therapy consisting of mycophenolate mofetil + oral steroids and placebo when combined with standard-of-care therapy
次要结局
- Proportion of patients who showing improvement in proteinuric at week 76(week 76)
- Proportion of patients achieving CRR with successful corticosteroid component at Week 76(Week 76)
- Proportion of patients who achieved ORR (CRR + PRR) at week 50(week 50)
- Proportion of patients who died, failed treatment or developed renal-related events by week 76(week 76)
研究者
相似试验
招募中
3 期
A MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-BLIND PHASE III CLINICAL TRIAL OF OBINUTUZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUSsystemic lupus erythematosusJPRN-jRCT2071230031Yoshiya Tanaka24
招募中
3 期
A MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-BLIND PHASE III CLINICAL TRIAL OF OBINUTUZUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITISupus NephritisJPRN-jRCT2011210059Tanaka Yoshiya24
招募中
不适用
A MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-BLIND PHASE III CLINICAL TRIAL OF OBINUTUZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUSsystemic lupus erythematosusjRCT2071230031Nippon Shinyaku Co., Ltd.24
进行中（未招募）
1 期
A trial to evaluate the effectiveness and safety of intravenous Sildenafil in the treatment of neonates with persistent pulmonary hypertension of the newborn or hypoxic respiratory failure and risk for PPHPersistent pulmonary hypertension of the newbornEUCTR2012-002619-24-ITPfizer Inc., 235 East 42nd Street, New York, NY 1001764
进行中（未招募）
1 期
A trial to evaluate the effectiveness and safety of intravenous Sildenafil in the treatment of neonates with persistent pulmonary hypertension of the newborn or hypoxic respiratory failure and risk for PPHMedDRA version: 18.0Level: LLTClassification code 10053592Term: Newborn persistent pulmonary hypertensionSystem Organ Class: 100000004850Persistent pulmonary hypertension of the newbornEUCTR2012-002619-24-FRPfizer Inc., 235 East 42nd Street, New York, NY 1001759